MedMen Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:$15.1B
Lead Investor(s):Wicklow Capital

Estimated Revenue & Financials

  • MedMen's estimated annual revenue is currently $200.3M per year.(?)
  • MedMen received $250.0M in venture funding in March 2019.
  • MedMen's estimated revenue per employee is $270,000
  • MedMen's total funding is $15.1B.

Employee Data

  • MedMen has 742 Employees.(?)
  • MedMen grew their employee count by 33% last year.
  • MedMen currently has 10 job openings.

MedMen Enterprises is the United States' preeminent cannabis company with multiple assets and operations in California, Nevada and New York. Combined, these key strategic states account for nearly half of North America's addressable legal market. MedMen owns and operates licensed cannabis facilities in cultivation, manufacturing and retail, and is the most recognized cannabis brand in the world today. MedMen brings class leading operational expertise and unprecedented investment to the fast changing and fast-growing cannabis industry as it moves from its gray market legacy to a fully regulated, legitimate and commercially viable market. Based in Los Angeles, MedMen employs nearly 800 workers across the U.S. It was founded in 2010 by Adam Bierman and Andrew Modlin, two visionary entrepreneurs who saw not just a tremendous business opportunity in the growing legalization of marijuana, but a chance to re-define our society's relationship with cannabis. The federal prohibition has had a disastrous impact, overpopulating our prisons and enriching violent drug cartels while keeping a relatively benign substance with proven benefits out of the reach of law abiding citizens. MedMen supports sensible, clear and just drug laws that strengthen communities and create economic opportunities. The company is the single largest financial supporter of progressive marijuana laws at the local, state and federal levels, giving directly to pro-legalization groups, industry organizations and political candidates. For more information, visit